Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
662 INR | -0.53% | -3.93% | -5.58% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 55.63 and 48.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.58% | 3.19B | C+ | ||
+46.19% | 56.65B | B- | ||
-6.14% | 39.44B | B | ||
+39.19% | 39.03B | A | ||
-6.65% | 26.86B | C | ||
+12.33% | 26.75B | B- | ||
-21.78% | 19.03B | B | ||
-0.35% | 12.28B | B+ | ||
+24.18% | 12.26B | B+ | ||
+28.38% | 12.04B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SYNGENE Stock
- SYNGENE Stock
- Ratings Syngene International Limited